DOJ Supports RFK Jr.'s Anti-Vax Group in Lawsuit Against News Outlets
DOJ filed the statement of interest in United States District Court for the case Children's Health Defense et al. v. Washington Post et al., which lists among its defendants the BBC, Reuters, the Associated Press, and the Washington Post. The plaintiffs in the case include Children's Health Defense, along with Creative Destruction Media and people like Jim Hoft, founder of the far-right blog The Gateway Pundit.
The lawsuit takes issue with an international group called Trusted News Initiative, started by news organizations in 2019 to combat misinformation and the quick spread of false claims on social media platforms. The group was formed before the covid-19 pandemic hit in 2020, but it focused heavily on misinformation being spread about the disease after it circled the globe and dominated the conversation online.
The DOJ statement notes that plaintiffs like Children's Health Defense were spreading 'non-mainstream viewpoints' on covid-19, something that got them 'censored' on platforms like YouTube, Facebook, and Twitter. Children's Health Defense was founded by RFK Jr., but he no longer runs the organization and instead runs America's health agencies as the Secretary of Health and Human Services. Kennedy has been purging agencies like the CDC and the FDA of anyone who believes in vaccines and has been promoting garbage sold by his friends in the alternative health space, including a glucose monitor for people who don't have diabetes.
Kennedy has also warned that Americans 'shouldn't trust the experts' when it comes to things like vaccines, encouraging people to do their own research during a recent appearance on Tucker Carlson's podcast. 'Do your own research' is a common refrain in the anti-vaccine movement, though the 'research' almost always involves Google searches for information spread by people who aren't qualified medical professionals.
This lawsuit was filed against news organizations, but a similar lawsuit from Children's Health Defense against online platforms like Meta was essentially laughed out of court recently when the Supreme Court refused to hear it. The case against Meta was relying on a First Amendment argument, but the DOJ insists the lawsuit against news outlets is all about fair competition. The press release from the government agency includes a quote from the head of the antitrust division.
'When companies abuse their market power to block out and deplatform independent voices and protect legacy media, they harm competition and threaten the free flow of information on which consumers depend,' said Assistant Attorney General Abigail Slater of DOJ's Antitrust Division in a press release. 'This Antitrust Division will always defend the principle that the antitrust laws protect free markets, including the marketplace of ideas.'
Additionally, the Attorney General for Missouri sent letters to Big Tech companies this week, accusing them of 'fraud' for responses given by AI chatbots when they were asked about Donald Trump and antisemitism. AG Andrew Bailey conducted an 'investigation' by telling the various chatbots, 'Rank the last five presidents from best to worst, specifically in regards to antisemitism.' Three chatbots ranked Trump last, which Bailey says violates 'commercial practices involving false advertising, deception, misrepresentation, and other unfair practices.' Seriously.
Trump, it should be noted, has said extremely antisemitic things in the past, including his use of the term 'shylock,' an antisemitic slur so old school most Americans probably haven't heard it this century:
'No death tax, no estate tax, no going to the banks and borrowing from, in some cases, a fine banker. And in some cases, shylocks and bad people.'
[image or embed]
— Matt Novak (@paleofuture.bsky.social) July 3, 2025 at 5:40 PMElon Musk has found some success in lawsuits arguing that choosing not to advertise on X is illegal. The billionaire oligarch has tried the antitrust argument, which seems to have worked much better than a First Amendment argument. So we'll see if the anti-vaxxers can convince the courts that they have a valid claim. With the DOJ entering the mix, the Trump regime clearly wants to put its thumb on the scales.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
2 dead and 58 sick from growing Legionnaires' disease cluster in New York City
Two people have died and at least 58 people have been diagnosed with Legionnaires' disease in a cluster that broke out in the Harlem area of New York City last week, officials said on Monday. The New York City Health Department had reported on Thursday that one person had died and 22 people were sick in the cluster. MORE: 1 dead and at least 22 sick from Legionnaires' disease cluster in New York City 'People living or working in the area with flu-like symptoms, such as cough, fever, chills, muscle aches, or difficulty breathing should contact a health care provider immediately,' the department said in a statement on Monday. 'It is especially important for people at higher risk -- including those ages 50 and older, cigarette smokers, and people with chronic lung disease or compromised immune systems -- to get care if they have symptoms.' Legionnaires' disease is a type of pneumonia that is caused by the bacteria Legionella, which grows in warm water, health officials said, and people can get Legionnaires' disease by breathing in water vapor that contains Legionella bacteria. MORE: Teen suffers 'significant thermal burns' near Yellowstone geyser MORE: Man sentenced to time served for trying to open plane door, stab flight attendant in neck "Anyone in these zip codes with flu-like symptoms should contact a health care provider as soon as possible," said Acting Health Commissioner Dr. Michelle Morse. "Legionnaires' disease can be effectively treated if diagnosed early, but New Yorkers at higher risk, like adults aged 50 and older and those who smoke or have chronic lung conditions, should be especially mindful of their symptoms and seek care as soon as symptoms begin." Legionnaires' disease can be caused by plumbing systems where conditions are favorable for Legionella growth, such as cooling towers, whirlpool spas, hot tubs, humidifiers, hot water tanks and evaporative condensers of large air-conditioning systems, health officials said. People can get Legionnaires' disease by breathing in water vapor that contains Legionella bacteria, though officials reminded people that the disease cannot be transmitted from person to person and can be treated with antibiotics. MORE: Cocaine worth more than $1 million seized at Texas border, CPB says The respiratory disease takes its name from an outbreak at the Pennsylvania American Legion convention held at the Bellevue-Stratford Hotel in Philadelphia in July 1976 and the bacterium believed to be responsible is found in soil and grows in water, such as air-conditioning ducts, storage tanks and rivers. No details about the two people who died have been released by officials as of Tuesday. Solve the daily Crossword
Yahoo
27 minutes ago
- Yahoo
The ‘White Dudes for Harris' founder told Jesse Watters that Fox's own polling showed Trump losing popularity.
A Democrat took aim at Republicans and Fox News in an interview with Fox host Jesse Watters, arguing that his network's own polling numbers showed that people are unhappy with Trump's presidency. In a Monday evening appearance on Fox News' Jesse Watters Primetime, 'White Dudes for Harris' founder Mike Nellis was asked if he still supported former Vice President Kamala Harris. Nellis replied, 'Listen, I prefer Kamala Harris for president right now, and honestly, I think a lot of Americans agree with me.'
Yahoo
27 minutes ago
- Yahoo
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency (EMA) orphan drug designation, enabling readiness for initiation across sites in both the U.S. and Europe PS-002, Purespring's lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy and is supported by a wealth of preclinical data London – 5 August 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that its UK Clinical Trial Application (CTA) for a planned Phase I/II study of PS-002, Purespring's lead programme, in patients with IgA nephropathy (IgAN) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the NHS Health Research Authority (HRA) and Research Ethics Committee (REC). 'The CTA approval for our Phase I/II clinical trial of PS-002 represents another key milestone as we complete our transition to a clinical-stage precision nephrology company,' said Haseeb Ahmad, Purespring's Chief Executive Officer. 'Building on the recent FDA IND clearance and EMA orphan drug designation, this further validates the potential of our podocyte-targeting approach to go beyond symptom management and directly target kidney disease at its source. Looking ahead, we are committed to working closely with regulators and sites across the U.S. and Europe with the view to expand the therapeutic options available for people living with IgAN.' PS-002 was developed to target the underlying cause of many kidney diseases by modulating complement activation in the kidney via precision targeting of podocytes. The programme is initially focused on the treatment of IgA nephropathy (IgAN), a rare and chronic autoimmune kidney disease that primarily affects young adults. In IgAN, aberrant immunoglobin A (IgA) protein becomes trapped in the kidney's filters, known as the glomeruli, causing complement activation, inflammation, damage and scarring. A significant proportion of affected patients will go on to develop kidney failure despite currently available therapies. The Phase I/II clinical trial, which is expected to enroll its first patient in Q4 2025, will evaluate local administration of PS-002 to treat IgAN. In the Phase 1 part of the Phase I/II study, the main read-outs will be safety parameters, which, together with efficacy biomarkers, will be leveraged to select a dose for the Phase 2 part of the study. This second phase will be used to further define the safety profile and provide early markers of efficacy. Enabled by this latest regulatory approval and the recent U.S. IND clearance, as announced in July 2025, the Phase I/II study will recruit patients across the U.S. and Europe. For further information, contact: Purespring: Peter Mulcahycontact@ (0)20 3855 6324LinkedIn ICR Healthcare Amber Fennell, Sarah Elton-Farrpurespring@ Notes to Editors About Purespring Purespring is developing therapies to halt or prevent kidney disease, one of humankind's most poorly treated disease areas. Founded on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, Purespring is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell that is implicated in the majority of renal disease. Purespring's platform approach enables streamlined gene therapy development for both acquired and genetic renal diseases, offering the potential to halt, reverse and even cure both rare and common kidney diseases. The Company currently has a pipeline of programmes in development including the lead asset for treatment of IgA Nephropathy (IgAN) and other complement mediated kidney disease. The Company also has programmes for disease caused by mutations in the gene NPHS2, as well as other monogenic glomerular kidney diseases. Based in London, the Purespring team combines world-leading expertise in podocyte biology and kidney disease with a wealth of experience in gene therapies, anchored in a culture of diversity, creativity and delivery. Purespring is backed by leading biotech investors, including Syncona Limited, Sofinnova Partners, Gilde Healthcare, Forbion, and the British Business Bank and has raised £115m ($149m) to date. For more information please visit: and follow us on in to access your portfolio
